MedPath

Level of DNA-fragmentation Before and After Antioxidant-based Therapies in Male Infertility

Not yet recruiting
Conditions
Infertility, Male
Registration Number
NCT06050031
Lead Sponsor
Janna Pape
Brief Summary

The investigators will investigate the effect of antioxidants and lifestyle factors on the level of oxidative stress. As oxidative stress cannot be directly measured, it will be approximated by the DNA fragmentation index (DFI) which reflects the level of DNA damage in sperm caused by oxidative stress.

Detailed Description

This is a one-site prospective exploratory study at the University Clinic for Gynaecological Endocrinology and Reproductive Medicine in Bern. On total 78 men with male infertility will be recruited.

The primary objective of the study is to assess the effectiveness of 3 months of antioxidant-based therapy on changing patients' DFI level.

The objective of the study is to assess the effect of 3 months of antioxidant-based therapy on the level of DFI. We are primarily interested in testing whether the treatment effectiveness (i.e. the change in DFI level) depends on the initial level (i.e. before treatment) and treatment adherence.

The data will be collected by the physicians and added to the REDcap study registry. Access to the total data set is only permitted for the principal investigator.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Male
Target Recruitment
78
Inclusion Criteria
  • Willing to participate
  • Written consent
  • Men with infertility problems who want to start an infertility treatment with their partner
Exclusion Criteria
  • No measurement of DNA fragmentation possible
  • Intake of prescribed medications
  • Exposure to toxins
  • Chronic diseases

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
DFIAt baseline and after three months of antioxidant-treatment

DNA-fragmentation measured by sperm-chromatin-structure-assay (SCSA)

Secondary Outcome Measures
NameTimeMethod
Sperm concentrationAt baseline and after three months of antioxidant-treatment

Sperm concentration \[10\^6/mL\]

Implantation rate10-12 days after timed intercourse, insemination or embryo transfer in the first treatment cycle after the antioxidant treatment

Endocrine pregnancy by measuring hCG in blood sample on day 10-12 after timed intercourse, insemination or embryo transfer

Clinical pregnancy rate5 weeks after timed intercourse, insemination or embryo transfer in the first treatment cycle after the antioxidant treatment

Clinical pregnancy confirmed by ultrasound, 5 weeks after timed intercourse, insemination or embryo transfer

Oxidation-reduction potential in ejaculateAt baseline and after three months of antioxidant-treatment

Oxidation-reduction potential \[mV/10-6 sperm/mL\]

Live birth rate9 months after timed intercourse, insemination or embryo transfer in the first treatment cycle after the antioxidant treatment

Birth of a living baby nine months after timed intercourse, insemination or embryo transfer

Alcohol consumptionAt baseline and during the three months of antioxidant-treatment

Alcohol consumption \[unit per week\]

BMIAt baseline and after the three months of antioxidant-treatment

BMI \[kg/m2\]

Sperm motilityAt baseline and after three months of antioxidant-treatment

Total sperm progressive motility \[%\] Oxidation-reduction potential \[mV/10-6 sperm/mL\]

Treatment adherenceDuring three months of antioxidants

Averaged missing capsules per week (100%, 75%, 50%, 25%) during treatment

SmokingAt baseline and during the three months of antioxidant-treatment

Cigarette consumption \[number of cigarettes per week\]

© Copyright 2025. All Rights Reserved by MedPath